Diagnostic work includes discovery and development of novel antimicrobial resistance diagnostics. Our portfolio includes development of molecular detection tools that are able to rapidly detect multiple biomarkers rapidly. Evaluation of these tests is progressing in collaboration with the Royal University Hospital Liverpool and in centres in Nepal and Malawi.

Emerging threats such as Zika and chikungunya have no vaccines or therapeutics available and few diagnostics. LSTM and UoL funded by an MRC Zika Rapid Response Initiative are working with industry collaborator developing novel point-of-care molecular diagnostics for the simultaneous diagnosis of Zika, chikungunya and dengue infections in Latin America.